Home Forums All Categories Non Invasive Bladder Cancer Genetic testing to find out if BCG has worked?

  • Genetic testing to find out if BCG has worked?

    Posted by arpegio2018 on July 30, 2018 at 7:49 pm

    I read a few weeks ago at the Sloan Kettering website that progress has been made in developing a test that would allow treatment to be either more precise or to find out, for example, if BCG treatment has worked effectively. And, if BCG has not been effective what is the best likely follow up treatment. Unfortunately not much else have I been able to discern with making a trip to NY to consult.
    Does anyone in this Forum have any information about this?
    Thank you.

    Alan replied 6 years, 6 months ago 4 Members · 6 Replies
  • 6 Replies
  • Alan's avatar

    Alan

    Member
    August 23, 2018 at 4:47 pm

    arpegio2018,

    It has been 10 years since I had a similar discussion with my doc. At that time his answer was “bladder cancer is simply not sexy enough to attract much research”. I do believe it is slowly changing. MD. Anderson and Dr. Kamat and his group have done studies along the fringes of your subject. Frustrating isn’t it, especially when BC is the #5 cancer.


    DX 5/6/2008 TAG3 papillary tumor .5 CM in size. 2 TURBS followed by 6 instillations of BCG weekly with a second round of 6 after a 6 week wait.
  • Arpegio2018's avatar

    Arpegio2018

    Member
    August 22, 2018 at 4:09 pm

    Thank you, Jack.

    Since I posted I received a short reply from Dr. Redelman-Sidi. He says ” While we continue to work on this issue, we do not yet have a test to predict BCG success.”

    But more interesting, at a recent SIU Conference Dr. Kamat of MD Anderson made an outstanding presentation case for Gene Therapy when BCG is unresponsive. Here is the link:

    https://www.urotoday.com/video-lectures/bladder-cancer/video/mediaitem/955-embedded-media2018-05-19-18-30-37.html

  • jack-r's avatar

    jack-r

    Member
    August 22, 2018 at 7:11 am

    Arpegio

    The Article you mention was first posted on-line one week ago (International Consultation on Bladder Cancer 2017). It is from a Springer publication, ‘World Journal of Urology’. Only the abstract is available without cost. Springer lists the full article as purchase only at the present time.

    From the conflict of interest disclosures, “This article does not contain any studies with human participants or animals performed by any of the authors.” The article is thus review in nature.

    Your post mentions a Dr Glickman and a Dr. Bernard H Bochner. Dr. Bochner is one of authors of the article.

    Dr. Gil Redelman-Sidi, MD is a researcher at MSCC in the Glickman Lab, his research page is at:
    https://www.mskcc.org/research/ski/labs/members/gil-redelman-sidi
    A list of his projects are on the site and may offer some insight.

    Good luck in your research on cutting edge research.

    Best,
    Jack


    6/2015 HG Papillary & CIS
    3 Years and 30 BCG/BCG+Inf
    Tis CIS comes back.
    BC clear as of 5/17 !
    RCC found in my one & only kidney 10/17
    Begin Chemo; Cisplatin and Gemzar
    8/18 begin Chemo# 3
    Begin year 4 with cis
    2/19 Chemo #4
    9/19 NED again :)
    1/2020 CIS is back
    Tried Keytruda, stopped by side effects
    Workin on a new plan for 2021
  • Arpegio2018's avatar

    Arpegio2018

    Member
    August 21, 2018 at 6:58 pm

    Dear Sara Anne,
    1. This is the statement from MSK I was referring to. I have written to the three Drs. mentioned without response so far.
    “Dr. Glickman’s laboratory is now collaborating with urologic surgeon Bernard H. Bochner to explore the clinical implications of this discovery — particularly, whether analyzing a patient’s bladder cancer cells can reliably predict his or her responsiveness to BCG therapy.
    With the support of a grant from The Society of MSKCC, Dr. Redelman-Sidi is trying to develop a lab test that would analyze urine samples, which usually contain cancer cells shed from the bladder. These cells could be tested both for their tendency to take up BCG and also for the presence of BCG-activating, cancer-causing mutations.
    “This would allow us to screen early-stage patients routinely before starting BCG therapy to make sure it’s the best course of treatment,” Dr. Glickman says.”
    2. Have you had access to this:
    “Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC)- 2017”. It is not among the ABCS resources but it seems quite important and it is different than the Consensus Statement.

  • Arpegio2018's avatar

    Arpegio2018

    Member
    July 31, 2018 at 6:00 pm

    Thanks. I have written them to ask several weeks ago and no reply.
    Surely a fellow BCG traveller has similar questions. A lot has happened in this field in recent years.

  • sara.anne's avatar

    sara.anne

    Member
    July 31, 2018 at 5:47 pm

    I would suggest that you call or write to Sloan-Kettering and ask them this question .

    Sara Anne


    Diagnosis 2-08 Small papillary TCC; CIS
    BCG; BCG maintenance
    Vice-President, American Bladder Cancer Society
    Forum Moderator

Sign In to reply.